Abstract: A custom cannabis extract dispenser for dispensing a cannabis extract into a container is provided. The custom cannabis extract dispenser includes several reservoirs for containing the various ingredients that will make up the final extract. The ingredients include purified cannabinoids, namely THC, CBD, minor cannabinoids, and various flavorants. A fluid management system in communication with a computer controller enables a user to select the amounts of the various ingredients desired in a custom cannabis extract.

Abstract: A non tobacco, cannabis based moist snuff composition is provided. The composition includes an herbal component primarily made up of cannabis leaves and/or stems and a casing component. Methods for producing a nontobacco cannabis based moist snuff composition are also provided. The method includes the steps of separating the leaves and stems from the cannabis plant, drying and curing them and mixing them with a casing component.

Abstract: Compositions and methods useful for providing negative control formulations for clinical trials involving whole plant cannabis extracts are provided. The formulations include a plurality of odorants and flavorants designed to mimic the unique odor and flavor profile of whole plant cannabis extracts. The odorants and flavorants may include the terpenes and terpinoids.

Abstract: The present invention provides aqueous formulations containing at least one cannabinoid, such as, for example, tetrahydrocannabinol (THC), cannabidiol (CBD), and a sulfoalkyl ether cyclodextrin. The liquid formulations are substantially clear, sterilizable, and chemically and physically stable. The liquid formulations do not precipitate upon dilution with distilled water or other pharmaceutically acceptable liquid carrier. The sulfoalkyl ether cyclodextrin-containing formulation provides significant advantages over other cyclodextrin-containing formulations of cannabiniods. The formulation can be prepared in acidic, neutral and slightly basic medium while providing acceptable concentrations of at least one cannabinoid suitable for administration. An SAE-CD-containing formulation of at least one cannabinoid can be provided in liquid form or as a reconstitutable solid. Solutions can be made either dilatable or non-dilutable with water at room temperature or under conditions typically encountered in the clinic.

Abstract: A substantially pure fraction of at least one cannabinoid is added to smokable or smokeless tobacco products to reduce the harm associated with tobacco use. The harm to be reduced includes irritation and carcinogenicity of tobacco. In a preferred embodiment a whole plant cannabis extract is mixed directly with the tobacco during the curing or manufacturing process. For cigarette applications the cannabinoids may be inserted into a cigarette filter, and/or paper. In other embodiments the cannabinoids are purified.

Abstract: The present invention relates to systems and methods for rapidly and accurately communicating the ratio of various cannabinoids contained in a cannabis containing product. Particularly the methods involve the steps of determining the ratio of THC to CBD in the product, assigning a color to be associated with that ratio and labeling the cannabis containing product with a label that prominently features that color.

Abstract: The present invention relates to the use of cannabis and cannabinoids, particularly cannabidiol (CBD) and tetrahydrocannabinol (THC) or derivatives thereof in the manufacture of a medicament for the treatment of symptoms associated with antidepressant cessation. Preferably the ratio of the CBD type compounds to the THC type compounds is between about 20:1 and 1:20. More preferably the CBD and THC type compounds or derivatives thereof are in the form of plant extracts.

Abstract: The disclosure is directed to a new and distinct cultivar of Cannabis Sativa plant named ‘Katelyn Faith’, characterized by a high amount of Cannabidiol (CBD)(13.5%) and a low amount of Tetrahydrocannabinol (THC)(0.